HSD11B1 is well-known to play a pathogenic role in obesity, the metabolic syndrome and type 2 diabetes mellitus, and HSD11B1 inhibitors are currently being studied in both animals and humans as possible pharmacotherapies [47]. This evidence concerns the gene HSD11B1 and metabolic syndrome.